ReviewNature reviews. Genetics2009
Plasma lipoproteins: genetic influences and clinical implications.
Review in Nature reviews. Genetics, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 181 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
181 citing papers in PubMed, 4 syntheses or guidelines pooled it, 463 citations in OpenAlex.
- Genetic Assessment and Clinical Correlates in Severe Hypertriglyceridemia: A Systematic Review.Genes · 2025Pooled it
- Inverse association between serum lipid profiles and hepatocellular carcinoma risk: a meta-analysis of epidemiological studies.Frontiers in oncology · 2025Pooled it
- Volanesorsen to treat severe hypertriglyceridaemia: A pooled analysis of randomized controlled trials.European journal of clinical investigation · 2022Pooled it
- Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci.American journal of human genetics · 2012Pooled it
- Six years' experience with LipidSeq: clinical and research learnings from a hybrid, targeted sequencing panel for dyslipidemias.BMC medical genomics · 2020Trial
- Brain education-based meditation for patients with hypertension and/or type 2 diabetes: A pilot randomized controlled trial.Medicine · 2019Trial
- Associations between pyrethroid insecticide concentrations and dyslipidemia: Findings from the Dongfeng-Tongji cohort.Science advances · 2026Article
- Association of the atherogenic index of plasma combined with obesity indices with cardiovascular disease and mortality.Lipids in health and disease · 2026Article
- Cholesterol Metabolism: An Ally in the Development and Progression of Cervical Cancer.International journal of molecular sciences · 2026Review
- Cholesterol: Facts and Opinions by a Non-lipid Cardiologist.Methodist DeBakey cardiovascular journal · 2026Review
- Genetic testing in individuals with extreme HDL-C levels: Diagnostic yield and clinical implications from the Tromsø Study.PloS one · 2026Article
- Genetic and Conventional Risk Stratification Are Complementary for Primary Prevention of CAD.Methodist DeBakey cardiovascular journal · 2026Review
- Innovative methods in evaluating the effects of lipid-lowering medication on bone tissue.Scientific reports · 2025Article
- Depletion of Hepatic SREBP2 Protects Against Hypercholesterolemia and Atherosclerosis through the ANGPTL3-LPL Axis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- From Genetic Findings to new Intestinal Molecular Targets in Lipid Metabolism.Current atherosclerosis reports · 2025Review
- Oxidative stress markers and atherogenic lipid alterations among chronic smokers.Bioinformation · 2025Article
- Causal relationship between plasma lipidome and rosacea: a Mendelian randomization analysis.Frontiers in endocrinology · 2025Article
- A small molecule esculetin accelerates postprandial lipid clearance involving activation of C/EBPβ and CD36-mediated phagocytosis by adipose tissue macrophages.Theranostics · 2025Article
- Review
- Aberrant Lipid Metabolism and Complement Activation in Age-Related Macular Degeneration.Investigative ophthalmology & visual science · 2024Review
121 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Susceptibility to the growing global public health problem of cardiovascular disease is associated with levels of plasma lipids and lipoproteins. Several experimental strategies have helped us to clarify the genetic architecture of these complex traits, including classical studies of monogenic dyslipidaemias, resequencing, phenomic analysis and, more recently, genome-wide association studies and analysis of metabolic networks. The genetic basis of plasma lipoprotein levels can now be modelled as a mosaic of contributions from multiple DNA sequence variants, both rare and common, with varying effect sizes. In addition to filling gaps in our understanding of plasma lipoprotein metabolism, the recent genetic advances will improve our ability to classify, diagnose and treat dyslipidaemias.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.